August 11, 2015
Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person’s cancer, report University of California, San Diego School of Medicine researchers in the Journal of Oncology Practice.
August 12, 2014
Oncologists at UC San Diego Moores Cancer Center are the first in San Diego to meld MRI technology with a traditional ultrasound prostate exam to create a three-dimensional map of the prostate that allows physicians to view growths that were previously undetectable.
March 17, 2014
…Mike Haynes and Charlie Joiner. All proceeds will benefit prostate cancer research at UC San Diego Moores Cancer Center.
February 24, 2022
UC San Diego Health is the first hospital system in San Diego County to employ high-intensity, focused ultrasound (HIFU) for minimally invasive prostate cancer treatment.
September 25, 2015
…NFL on FOX, John Lynch. All proceeds will benefit prostate cancer research at Moores Cancer Center at UC San Diego Health.
July 27, 2020
Researchers at Ludwig Institute for Cancer Research and University of California San Diego School of Medicine report that inhibiting a key enzyme caused human cancer cells associated with two major types of breast and ovarian cancer to die and in mouse studies reduced tumor growth.
February 23, 2021
Scientists at University of California San Diego School of Medicine validated a more inclusive and comprehensive genetic tool, known as a polygenic hazard score (PHS), for predicting age of onset of aggressive prostate cancer.
January 6, 2015
…a novel imaging technique that measurably improves upon current prostate imaging – and may have significant implications for how patients with prostate cancer are ultimately treated.
July 17, 2012
…a genetic test to predict a man’s risk for prostate cancer. Use of the test could reduce the need for repeat biopsies in men who have had a negative biopsy.
October 5, 2022
UC San Diego Health is the first hospital system in the region to offer a novel treatment option for patients with prostate cancer that has spread throughout the body and has not responded to other therapeutics.
